FindTrial
Sign In

Effect of zinc supplementation to antidepressant therapy in patients with unipolar depression

Effect of zinc supplementation on antidepressant therapy and serum zinc level in unipolar depression:A randomized double blind controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/01/007751
Enrollment
60
Registered
2017-01-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Unipolar depression

Interventions

Intervention1: zinc: zinc 20mg OD for 08 weeks Control Intervention1: without zinc: only antidepressant Control Intervention2: Nil: Only on antidepressants for 8 weeks

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Diagnosed cases of depressive episode and recurrent depressive disorder according to ICD-10 DCR (WHO, 1993). 2.Status of patient should be drug naïve or drug free for minimum 2 weeks. 3.Patients giving written informed consent.

Exclusion criteria

Exclusion criteria: 1.Presence of comorbid psychiatric disorder. 2.Individuals with history of substance use meeting dependence criteria, other than nicotine and caffeine. 3.Co-morbid medical illness known to affect zinc level including acute or chronic inflammatory disorder and neurological disorder. 4.ECT during index episode. 5.Patient on multivitamin supplementation.

Design outcomes

Primary

MeasureTime frame
MEAN HAMILTON DEPRESSION SCORE AND MEAN BECK DEPRESSION SCORETimepoint: BASELINE,2 WEEK,4 WEEK & 8 WEEK—

Secondary

MeasureTime frame
MEAN SERUM ZINC,ALBUMIN AND C-REACTIVE PROTEIN LEVELTimepoint: BASELINE,2 WEEK,4 WEEK & 8 WEEK—

Countries

India

Contacts

Public ContactDr Basudeb Das

CENTRAL INSTITUTE OF PSYCHIATRY

basudeb71@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026